The new centers are enrolling patients in a randomized, placebo-controlled trial to test the efficacy of the experimental vaccine, which is being developed by the company AstraZeneca.
The vaccine trial is seeking 30,000 patients globally between the ages of 18 and 85, each of whom will receive two doses of either the vaccine or a placebo saline solution.
“Our new locations bring cutting-edge medical research to patients that we serve,” said Dr. Mark Mulligan, director of the Division of Infectious Diseases and Immunology and Vaccine Center at NYU Langone Health, “including those currently underrepresented in clinical trials such as Black, Hispanic and elderly people who are at higher than average risk of COVID-19 infection.”
Other high-risk patients for COVID-19 include those with underlying conditions like heart disease, hypertension, asthma, chronic obstructive pulmonary disease, diabetes or autoimmune disease.
NYU Langone Health is one of 10 National Institutes of Health (NIH)-funded Vaccine and Treatment Evaluation Units in the country. Its work is supported by the National Institute of Allergy and Infectious Diseases (NIAID), which is led by Dr. Anthony Fauci. The hospital system was selected through a competiive grant process.
Dr. Stephanie Sterling, chief of infectious disease and hospital epidemiologist at NYU Langone Hospital–Brooklyn, said the expansion of the Vaccine Center to the borough is an “enormous opportunity” that will have meaningful impact in the effort to develop a COVID-19 vaccine.
“Diversity in clinical trial enrollment is critical to ensuring the safety and efficacy of a vaccine,” Sterling said, “and we are grateful to have wonderful community partners in Brooklyn to help bring an end to this international public health crisis.”
To express interest in COVID-19 vaccine trial enrollment, visit nyulmc.org/covidvaccine.